Want to see SE:VIVE full AI Analyst Report?
VIVE Stock Chart & Stats
kr0.08
>-kr0.01(-0.59%)
At close: 4:00 PM EST
kr0.08
>-kr0.01(-0.59%)
Day’s Range― - ―
52-Week Rangekr7.00 - kr27.82
Previous CloseN/A
Volume772.68K
Average Volume (3M)410.92K
Market Cap
kr92.78M
Enterprise Valuekr34.74
Total Cash (Recent Filing)kr31.48M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding11,071,369
10 Day Avg. Volume214,919
30 Day Avg. Volume410,918
Financial Highlights & Ratios
PEG Ratio8.38
Price to Book (P/B)58.31
Price to Sales (P/S)0.00
P/FCF Ratio-165.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA low debt burden (debt-to-equity ~0.10) gives the company greater financial flexibility despite operating losses. Manageable leverage reduces solvency risk, preserves the ability to fund R&D or seek partnerships without immediate refinancing pressure, a durable structural benefit.
Proprietary Delivery PlatformOwning proprietary formulation and drug-delivery platforms focused on oncology creates a durable competitive asset. The business model emphasizes R&D plus partnering/licensing, enabling value creation via collaborations and milestone-driven revenues without requiring large commercial infrastructure.
Improving Cash Burn TrendYear-over-year reduction in operating cash burn signals improving cost control or program prioritization. While still negative, a sustained trend toward lower cash consumption extends runway and strengthens the likelihood management can reach value-driving milestones or secure less dilutive partnerships.
Bears Say
No Recent RevenueAbsence of reported revenue in 2024–2025 removes a core proof point for commercial viability and limits margin visibility. Over a multi-month horizon, lack of product-derived cash inflows increases reliance on financing or partnerships and makes long-term operating self-sufficiency uncertain.
Sustained Cash BurnConsistent negative operating and free cash flow indicates the company is not self-funding its development activities. Persistent burn forces reliance on capital markets or deal-making, increasing dilution risk and constraining strategic optionality over the medium term.
Eroding Equity / Negative ReturnsMaterial decline in shareholder equity and persistently negative ROE reflect capital erosion from losses. A diminished capital cushion reduces resilience to setbacks and increases the likelihood of future dilutive financing or strategic trade-offs, weakening long-term shareholder protections.
Vivesto AB News
VIVE FAQ
What was Vivesto AB’s price range in the past 12 months?
Vivesto AB lowest stock price was kr7.00 and its highest was kr27.82 in the past 12 months.
What is Vivesto AB’s market cap?
Vivesto AB’s market cap is kr92.78M.
When is Vivesto AB’s upcoming earnings report date?
Vivesto AB’s upcoming earnings report date is Aug 13, 2026 which is in 8 days.
How were Vivesto AB’s earnings last quarter?
Vivesto AB released its earnings results on May 07, 2026. The company reported -kr0.838 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.838.
Is Vivesto AB overvalued?
According to Wall Street analysts Vivesto AB’s price is currently Overvalued.
Does Vivesto AB pay dividends?
Vivesto AB does not currently pay dividends.
What is Vivesto AB’s EPS estimate?
Vivesto AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB have?
Vivesto AB has 11,071,369 shares outstanding.
What happened to Vivesto AB’s price movement after its last earnings report?
Vivesto AB reported an EPS of -kr0.838 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Vivesto AB?
Currently, no hedge funds are holding shares in SE:VIVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivesto AB
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
Technical Analysis
AlzeCure Pharma AB
―
Gabather AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―